matt_heil

Curemark announces executive promotions

pharmafile | July 18, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Curemark 

Curemark has announced the appointment of Matthew Heil to the position of chief scientific officer. 

Currently, Dr Heil is serving as Curemark’s senior vice president for Research and Product Development.  

Additionally, Curemark has announced the appointment of James Szigethy to the position of vice president of Research and Product Development from director of Research and Product Development.

Advertisement

Curemark founder and chief executive Dr Joan Fallon, said: “Dr Heil’s contributions and strategic insight into our product pipeline as well as our Phase III trial for CM-AT in autism have been invaluable. As we maximise the value of our products and platform, Dr Heil is the perfect person to lead the charge. He is an accomplished scientist and wonderful collaborator.”

Heil commented: “Working on the development of Curemark’s autism product has been the highlight of my professional career. Leading Curemark’s scientific team is a very exciting opportunity and I’m thrilled that I will be able to work closely with James Szigethy in his new capacity as we move to optimise our product pipeline.”

Heil has more than two decades of experience in the pharmaceutical and biotechnology industries, and has served on multiple corporate boards. His areas of work include product development, regulatory affairs, strategic partnering and epidemiologic analysis.

Related Content

No items found
The Gateway to Local Adoption Series

Latest content